参考文献/References:
[1] Jiang G,Wang D, Li W,et al. Coronary heart disease mortality in China: age, gender, and urban-rural gaps during epidemiological transition[J].Rev Panam Salud Publica,2012,31(4):317-324.
[2] Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation[J].Circulation,2011,124(22):2458-2473.
[3] Choudhry NK, Glynn RJ, Avorn J, et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes:medication adherence and clinical outcomes[J].Am Heart J,2014,167(1):51-58.
[4] Ho PM, Bryson CL, Rumsfeld JS. Medication adherence:its importance in cardiovascular outcomes[J]. Circulation,2009,119(23):3028-3035.
[5] Chowdhury R, Khan H, Heydon E, et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences[J].Eur Heart J,2013,34(38): 2940-2948.
[6] Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries(the PURE study):a prospective epidemiological survey[J]. Lancet,2011,378(9798):1231-1243.
[7] Naderi SH, Bestwick JP, Wald DS. Adherence to drugs that prevent cardiovascular disease: meta-analysis on 376 162 patients[J].Am J Med,2012,125(9):882-887.
[8] Rossi E,Perman G, Michelangelo H, et al. Medication adherence to secondary prevention for coronary artery disease[J]. Medicina(B Aires),2014,74(2):99-103.
[9] Valle JA,Ho PM. Medication adherence in secondary prevention post-myocardial infarction[J].Curr Treat Options Cardiovasc Med,2014,16(12):349.
[10] Wroe AL. Intentional and Unintentional nonadherence:a study of decision-making[J].J Behav Med,2002,25(4):355-372.
[11] Wallach-Kildemoes H, Andersen M, Didreichsen F, et al. Adherence to preventive statin therapy according to socioeconomic position[J].Eur J Clin Pharmacol, 2013,69(8):1553-1563.
[12] Lewey J, Shrank WH, Bowry AD, et al. Gender and racial disparities in adherence to statin therapy: a meta-analysis[J].Am Heart J,2013,165(5):665-678.
[13] Bauer LK, Caro MA, Beach SR, et al. Effects of depression and anxiety improvement on adherence to medication and heathy behaviors in recently hospitalized cardiac patients[J].Am J Cardiol,2012,109(9):1266-1271.
[14] Dempe C, Junger J, Hoppe S, et al. Association of anxious and depressive symptoms with medication nonadherence in patients with stable coronary artery disease[J]. J Psychosom Res,2013,74(2):122-127.
[15] Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States:a systematic review[J].Ann Intern Med,2012,157(11):785-795.
[16] Bosworth HB, Granger BB, Mendys P, et al. Medication adherence: a call for action[J]. Am Heart J,2011,162(3):412-424.
[17] Culig J, Leppée M. From Morisky to Hill-bone; self-reports scales for measuring adherence to medication[J].Coll Antropol,2014,38(1):55-62.
[18] Morisky DE, Ang A, Krousel-Wood M, et al. Predictive validity of a medication adherence measure in an outpatient setting[J].J Clin Hypertens(Greenwich),2008,10(5):348-354.
[19] Park LG,Howie-Esquivel J,Dracup K.Electronic measurement of medication adherence[J].West J Nurs Res,2015,37(1):28-49.
[20] Ho PM, Lambert-Kerzner A,Carey EP, et al. Multifaceted intervention to improve medication adherence and secondary prevention measures after acute coronary syndrome hospital discharge:a randomized clinical trial[J].JAMA Intern Med,2014,174(2):186-193.
[21] Rodriguez F,Cannon CP,Steg PG,et al. Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease:findings from the REACH Registry[J].Clin Cardiol, 2013,36(12):721-727
[22] Kimmel SE, Troxel AB, Loewenstein G, et al. Randomized trial of lottery-based incentives to improve warfarin adherence[J]. Am Heart J,2012,164(2):268-274.
[23] Park LG, Howie-Esquivel J, Chung ML, et al. A text messaging intervention to promote medication adherence among patients with coronary heart disease[J]. Patient Educ Couns,2014,94(2):261-268.
[24] Park LG,Howie-Esquivel J,Whooley MA,et al. Psychosocial factors and medication adherence among patients with coronary heart disease: a text messaging intervention[J]. Eur J Cardiovasc Nurs,2015,14(3):264-273.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(6):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(6):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(6):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(6):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(6):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(6):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(6):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[9]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(6):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[10]方砚 王效浣 郭朝霞.血流介导性血管扩张评价心血管病患者肱动脉内皮功能的研究进展[J].心血管病学进展,2019,(5):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]
FANG Yan,WANG Xiaohuan,GUO Zhaoxia.Flow- mediated Vasodilation Evaluation of Brachial Artery Endothelial Function in Patients with Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2019,(6):793.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.032]